Cangene's Chickenpox product granted orphan drug designation
"This designation is another step in our commitment to address the unmet medical need faced by susceptible individuals who are exposed to chickenpox. It builds on the expanded access investigational new drug protocol that was approved in January by the FDA," said Dr. John Langstaff, Cangene's president and chief executive officer.
VariZIG(TM) is a purified antibody preparation (hyperimmune) specific for Varicella zoster virus, which causes chickenpox and shingles.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.